Jonathan Zager MD

General Surgery•Tampa, FL

Melanoma, Surgical Oncology (Other than Breast)

Chief Academic Officer Designated Institutional Official Director of Regional Therapies Senior Member, Department of Cutaneous Oncology, Moffitt Cancer Center Professor of Surgery and Chair of the Department of Oncologic Sciences, USF-Morsani College of Medicine.

Request appointment

10920 North McKinley DriveTampa, FL 33612
Book by Phone+1(659) 246-7097

Overview of Dr. Zager

Jonathan Zager, MD, based in Tampa, FL, is a surgical oncologist, specializing in melanoma, skin cancers and sarcoma oncology. He completed his medical education at Tel Aviv University Sackler School of Medicine, followed by residencies and fellowships at Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of Texas MD Anderson Cancer Center. Dr. Zager serves as the Chief Academic Officer at H. Lee Moffitt Cancer Center and a professor of surgery and chair of the Department of Oncologic Sciences the University of South Florida Morsani College of Medicine. His clinical and research expertise encompasses various soft tissue carcinomas and melanoma, with over 400 publications, book chapters and edited textbooks, focusing on melanoma management and outcomes. Dr. Zager serves as an expert on regional therapies for complicated and unrespectable soft tissue malignancies, including isolated, limb infusion, and percutaneous hepatic Perfusion.He has also been involved as the principal investigator several clinical trials pertaining to melanoma and other cancers. Dr. Zager has received multiple CMS Meaningful Use Stage 1 Certifications, was recognized among the Best Doctors in America by Castle Connolly, has been awarded the educator or mentor of the year at Moffitt Cancer Center several times, and recognized as the physician of the year at Moffitt Cancer Center in 2024.

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 2004 - 2006
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Surgery, 2001 - 2004
Memorial Sloan Kettering Cancer CenterFellowship, Hepatobiliary Surgery, 1999 - 2001
Zucker School of Medicine at Hofstra/NorthwellResidency, Surgery, 1997 - 1999
Tel Aviv University SacklerClass of 1997

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

GA State Medical License 2014 - 2028
TX State Medical License 2004 - 2028
FL State Medical License 2006 - 2027
NY State Medical License 1998 - 2005
American Board of Surgery Surgery

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2016-2017
CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2016-2017
CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2016-2017

Clinical Trials

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas
TERMINATED
PHASE2
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Start of enrollment: 2010 Aug 13
COMPLETED
PHASE1
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Start of enrollment: 2012 Jul 27
COMPLETED
PHASE1

Publications & Presentations

PubMed

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.
Lilit Karapetyan, Jin Xu, Kimberly Ward, Denise Kalos, Benjamin Schachner
Med. 2026-08-14
Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma.
Sophie E Orme, Serigne N Lo, Robyn P Saw, Kerwin F Shannon, AndrewJ Spillane
Journal of the National Cancer Institute. 2026-06-15
ASO Visual Abstract: Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients With Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publica...
Eyal Mor, Sameer Apte, Mathias Bressel, Kristy K Broman, Tina J Hieken
Annals of Surgical Oncology. 2026-06-01

Journal Articles

Microsatellitosis in Patients with Melanoma
Richard L White, Mark B Faries, Stanley P Leong, Andrew J Sinnamon, Jane L Messina, Barbara A Pockaj, Giorgos C Karakousis, Edmund K Bartlett, John T Vetto, Vernon K S..., Annals of Surgical Oncology
Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?
C Wayne Cruse, Vernon K Sondak, Ricardo J Gonzalez, Daniel E Oliver, Jane L Messina, Louis B Harrison, Jonathan S Zager, Amod A Sarnaik, Annals of Surgical Oncology
Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
Jonathan S Zager, Amod A Sarnaik, Annals of Surgical Oncology

Press Mentions

Gene Expression Test Helps Identify Risk of Melanoma Spreading to Lymph NodesOctober 24th, 2025
Moffitt Study Shows Gene Expression Test Can Help Identify Melanoma Patients at Low Risk of Lymph Node SpreadOctober 23rd, 2025
Moffitt Study Reveals Gene Expression Test Accurately Identifies Melanoma Patients with Low Risk of Lymph Node MetastasisOctober 22nd, 2025

Committees

Chair, Disease Site Working Group - Melanoma/ Sarcoma. SSO

Professional Memberships

Society of Surgical Oncology - SSO
Member
American College of Surgeons - ACS
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS California CaliforniaCare HMO
BCBS California PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PPO
Pacificare HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment